CN108822126A - Thieno thiapyran formyl piperazine class compound and its medical usage - Google Patents

Thieno thiapyran formyl piperazine class compound and its medical usage Download PDF

Info

Publication number
CN108822126A
CN108822126A CN201810537980.7A CN201810537980A CN108822126A CN 108822126 A CN108822126 A CN 108822126A CN 201810537980 A CN201810537980 A CN 201810537980A CN 108822126 A CN108822126 A CN 108822126A
Authority
CN
China
Prior art keywords
thieno
thiopyran
dihydro
ylcarbonyl
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810537980.7A
Other languages
Chinese (zh)
Other versions
CN108822126B (en
Inventor
胡春
柯佳
闫燚思
路奇
黄二芳
徐赫男
印华润
张娟
张瑞
舒越
邓飘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenyang Pharmaceutical University
Original Assignee
Shenyang Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Pharmaceutical University filed Critical Shenyang Pharmaceutical University
Priority to CN201810537980.7A priority Critical patent/CN108822126B/en
Publication of CN108822126A publication Critical patent/CN108822126A/en
Application granted granted Critical
Publication of CN108822126B publication Critical patent/CN108822126B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The invention belongs to pharmaceutical technology field, be related to thieno thiapyran formyl piperazine class compound and its and preparation method thereof and as epidermal growth factor recipient tyrosine kinase inhibitor application.Compound, its pro-drug and the pharmaceutical active metabolite and its pharmaceutically acceptable salt as shown in logical formula (I), wherein：R is independently selected from hydrogen, methyl；R ' is independently selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl, cyano, halogen, amino, nitro, trifluoromethyl or trifluoromethoxy.

Description

Thienopyran formyl piperazine compound and medical application thereof
Technical Field
The invention belongs to the technical field of medicines, and relates to a thienothiopyran formyl piperazine compound, a preparation method thereof and application of the thienothiopyran formyl piperazine compound as an epidermal growth factor receptor tyrosine kinase inhibitor.
Background
The morbidity and mortality of various tumors in China have a remarkably rising trend in recent years, the tumors with the highest morbidity and mortality in men are lung cancer, and women are breast cancer and lung cancer. Unhealthy habits and habits such as smoking, excessive drinking, insufficient physical activities and the like, haze, and working and living pressure brought to people by rapid development of economic society and social transformation have inconsiderable influence on health, and the rising trend of the death rate of lung Cancer, liver Cancer, colorectal Cancer and breast Cancer related to environment and life style is more obvious, wherein the rising range of the lung Cancer and the breast Cancer is the largest, and the lung Cancer and the breast Cancer respectively rise by 465% and 96% in the last 30 years (StewartBW, Wild CP. WHO: World Cancer Report 2014.Lyon: International Agency for research on Cancer 2014.), so the prevention and treatment of the lung Cancer and the breast Cancer are the hot spots of the current research.
Based on the differentiation degree and morphological characteristics of cancer cells, a large number of dysregulated epidermal growth factor signaling and overexpression of epidermal growth factor receptor tyrosine kinase are found in many tumor patients. Epidermal Growth Factor Receptor (EGFR), a member of the receptor type tyrosine kinase family, is known as a transmembrane glycoprotein consisting of an extracellular epidermal growth factor binding region (comprising 621 amino acid residues), a hydrophobic transmembrane domain (23 amino acid residues), an intracellular kinase region (542 amino acid residues), and a carboxy-terminal four part. EGFR has 4 types of HER-1, HER-2, HER-3 and HER-4, and when a small molecule ligand is combined with EGFR to activate EGFR, and then a tyrosine kinase region of EGFR is activated to recognize a substrate enzyme of protein, a signal is transmitted into cells, and simultaneously after EGFR is activated, a plurality of downstream signal transduction paths can be activated to stimulate cell growth and proliferation (Zhang H, Berezv A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI ErbB receptors: om on genes to target cell survival observation. the Journal of Clinical Investigation,2007,117(8): 2051-2058.). The receptor type tyrosine kinase mainly has the difference of an extracellular ligand binding region, and an intracellular tyrosine kinase structural domain has higher homology.
The existing epidermal growth factor receptor tyrosine kinase inhibitors, such as gefitinib, erlotinib, lapatinib and the like, have the skin reactions of diarrhea, rash, pruritus and the like, and possible headache, prolongation of heart QT interval, reduction of bioavailability and the like (Liyingying, Tianchi, Wanglie, Ximengmeng, Chengzeng, research progress of small molecule epidermal growth factor receptor tyrosine kinase inhibitors, tumor pharmacy, 2016,6(2): 81-88.).
The thienothiopyran formyl piperazine compound is used as an epidermal growth factor receptor tyrosine kinase inhibitor with a brand new structure type, has the characteristics of novel structure type and equivalent or superior pharmacodynamic action to the existing medicaments, can be used for treating or preventing related diseases caused by the dysregulation of epidermal growth factor receptor signal conduction, such as non-small cell lung cancer, gastric cancer, breast cancer, ovarian cancer, renal cell carcinoma, colorectal cancer, bladder cancer and head and neck squamous cell carcinoma, and has good application value and development and application prospects.
Disclosure of Invention
The invention aims to provide a compound shown as a formula I, a prodrug, a pharmaceutically active metabolite and a pharmaceutically acceptable salt thereof, and provides application of the compound in preparation of medicines for preventing and treating diseases related to EGFR signaling dysregulation.
The present invention provides compounds of formula (I), prodrugs and pharmaceutically active metabolites thereof, and pharmaceutically acceptable salts thereof:
wherein:
r is independently selected from hydrogen, methyl;
r' is independently selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, cyano, halogen, amino, nitro, trifluoromethyl, or trifluoromethoxy.
Further, the air conditioner is provided with a fan,
r is selected from hydrogen and methyl;
r' is independently selected from hydrogen, methyl, ethyl, methoxy, ethoxy, hydroxy, cyano, fluoro, chloro, bromo, iodo, amino, nitro, trifluoromethyl, or trifluoromethoxy.
In particular, the amount of the solvent to be used,
r is selected from hydrogen and methyl;
r' is selected from hydrogen, methyl, ethyl, fluoro, chloro, bromo, trifluoromethyl or trifluoromethoxy, preferably hydrogen, 2-chloro, 2-ethyl, 4-fluoro, 2-trifluoromethoxy, 2, 4-dimethyl, 3-bromo, 2-methyl-6-chloro, 2-methyl-3-chloro, 4-bromo, 4-chloro, 3-trifluoromethyl-4-chloro, 2-methyl, 4-methoxy, 4-methyl, 3-trifluoromethyl, 2, 5-dimethyl, 2-fluoro, 3-chloro-4-fluoro, 3, 5-bis (trifluoromethyl), 3, 4-difluoro, or 3-bromo.
"pharmaceutically acceptable salts" refers to conventional acid addition salts or base addition salts which retain the biological effectiveness and properties of the compounds of formula I and which are formed with suitable non-toxic organic or inorganic acids or organic or inorganic bases, acid addition salts include hydrochloride, hydrobromide, hydroiodide, nitrate, phosphate, sulfate, perchlorate, thiocyanate, bisulfate, persulfate, borate, formate, acetate, propionate, valerate, pivalate, hexanoate, heptanoate, octanoate, isooctanoate, undecanoate, laurate, palmitate, stearate, oleate, cycloproponate, oxalate, malonate, succinate, maleate, fumarate, adipate, azelate, acrylate, strawberry, crotonate, tiglate, itaconate, sorbate, cinnamate, glycolate, lactate, malate, tartrate, citrate, tartrate, mandelate, prolinate, ascorbyl, gluconate, glucarate, mannitol, maleate, tartrate, phenate.
"pharmaceutically active metabolite" refers to a pharmaceutically acceptable and effective metabolite of a compound of formula I.
The invention also relates to a pharmaceutical composition for inhibiting epidermal growth factor receptor tyrosine kinase, which comprises the compound or the derivative of the formula I or the pharmaceutically applicable acid addition salt thereof and a pharmaceutically applicable carrier.
The term "halogen" as used in the present invention includes fluorine, chlorine or bromine.
"pharmaceutically acceptable" such as pharmaceutically acceptable carriers, excipients, prodrugs, etc., means pharmacologically acceptable and substantially non-toxic to a patient to whom a particular compound is administered.
"substituted," unless otherwise specified, means that the substituent may be present at one or more positions, the substituents being independently selected from a particular selection.
The compounds of the invention can be administered to a patient by various methods, such as orally in capsules or tablets, as sterile solutions or suspensions, and in some cases, intravenously in the form of solutions. The free base compounds of the present invention may be formulated and administered in the form of their pharmaceutically acceptable acid addition salts.
The thienothiopyran formyl piperazine compound, the prodrug thereof, the pharmaceutically active metabolite thereof and the pharmaceutically acceptable salt thereof can be combined with the existing medicaments or used independently for preparing the medicaments for treating related diseases of epidermal growth factor receptor signal transduction disorder.
The pharmaceutical composition can be combined with the existing medicines or used independently for preparing the medicines for treating related diseases of epidermal growth factor receptor signal transduction disorder.
The epidermal growth factor receptor is HER-1, HER-2, HER-3 or HER-4, wherein the related diseases of the dysregulation of the epidermal growth factor receptor signal transduction are non-small cell lung cancer, gastric cancer, breast cancer, ovarian cancer, renal cell carcinoma, colorectal cancer, bladder cancer and head and neck squamous cell carcinoma.
Methods of treatment and dosages used
The various diseases and conditions to be treated as described herein are well known and clear to those skilled in the art. It is also understood that one skilled in the art can treat a patient currently afflicted with a disease or condition with a therapeutically effective amount of the compound or affect the disease or condition by prophylactically treating a patient afflicted with a disease or condition.
The term "patient" as used herein refers to a warm-blooded animal, such as a mammal, having a tumor. It is understood that guinea pigs, dogs, cats, rats, mouse horses, cattle, sheep, and humans are examples of animals within the meaning of the term.
The term "therapeutically effective amount" as used herein refers to an amount effective for the control of tumor-associated diseases and conditions. The term "controlling" is intended to refer to all processes by which the progression of the diseases and conditions described herein can be slowed, interrupted, arrested or halted, and not necessarily the complete elimination of all of the symptoms of the disease and condition.
A therapeutically effective amount can be readily determined by the attending diagnostician as one skilled in the art using routine techniques and observing results obtained under analogous circumstances. In determining a therapeutically effective amount of a dosage, the attending diagnostician considers a number of factors, including but not limited to: the species of mammal; its size, age and general health; the specific diseases involved; the degree or complexity or severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; bioavailability characteristics of the administered formulation; a selected dosing regimen; concomitant medication use and other related conditions.
Therapeutically effective amounts of the active compounds are expected to vary from about 0.001 milligrams per kilogram of body weight per day (mg/kg/day) to about 100 mg/kg/day. Preferred amounts can be determined by one skilled in the art.
In effectively treating patients suffering from the diseases and conditions described above, such compounds may be administered in any form or manner that makes the compound bioavailable in therapeutically effective amounts, including oral, inhaled, and parenteral routes. For example, the compounds can be administered orally, by inhalation as an aerosol or dry powder, by subcutaneous injection, intramuscular injection, intravenous injection, transdermal administration, intranasal administration, rectal administration, topical administration, and the like. Oral or inhalation administration is generally preferred for the treatment of respiratory diseases such as asthma. One skilled in the art of formulating formulations can readily select the appropriate form and mode of administration depending on the particular characteristics of the compound selected, the condition of the disease or condition to be treated, the stage of the disease or condition, and other relevant circumstances.
The compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients in the form of pharmaceutical compositions, the proportions and properties of which are determined by the solubility and chemical properties of the compound selected, the route of administration selected, and standard pharmaceutical practice. The compounds of the present invention, while effective per se, may be formulated and administered in the form of their pharmaceutically acceptable salts, such as acid or base addition salts, for the purposes of stability, ease of crystallization, improved solubility, and the like.
The present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound admixed or otherwise associated with one or more pharmaceutically acceptable carriers or excipients.
The pharmaceutical compositions are prepared according to methods well known in the pharmaceutical art. The carrier or excipient which may serve as a vehicle or medium for the active ingredient may be a solid, semi-solid, or liquid material. Suitable carriers or excipients are well known in the art. The pharmaceutical compositions may be adapted for oral, inhalation, parenteral or topical use and may be administered to the patient in the form of tablets, capsules, aerosols, inhalants, suppositories, solutions, suspensions and the like.
The compounds of the present invention may be administered orally, for example, with an inert diluent or with an edible carrier, which may be enclosed in capsules or compressed into tablets. For oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These formulations should contain at least 4% of the compound of the invention, i.e. the active ingredient, but may vary depending on the particular form, conveniently between 4% and about 70% by weight of the unit. The amount of the compound present in the composition should be such that a suitable dosage is obtained. Preferred compositions and formulations of the present invention may be determined by one skilled in the art.
The tablets, pills, capsules, lozenges and the like may further contain one or more of the following adjuvants: binders such as microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch or lactose, disintegrants such as alginic acid, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil. Other dosage unit forms may contain other, different materials that modify the physical form of the dosage unit, for example as a coating. Syrups, in addition to containing the compound, may contain sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. The materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.
For parenteral administration, the compounds of the invention may be added to a solution or suspension. These formulations should contain at least 0.1% of the compound of the invention, but may vary between 0.1 and about 50% by weight of the formulation. The amount of compound present in such compositions should be such that a suitable dosage is obtained. Preferred compositions and vitex negundo can be determined by a person skilled in the art.
The compounds of the invention may also be administered by inhalation, for example as an aerosol or dry powder. May be released by a liquefied or compressed gas or by a suitable pumping system which dispenses the compounds of the invention or their formulations. Formulations for administration by inhalation of the compounds may be delivered in monophasic, biphasic or triphasic systems. For aerosol administration of the compounds, a number of systems are available. Dry powder formulations are prepared by granulating or milling the compound to the appropriate particle size or by mixing the granulated or milled compound with a suitable carrier, such as lactose or the like. Delivery systems by inhalation include the necessary containers, active agents, valves, sub-containers, and the like. Preferred aerosol and dry powder formulations for administration by inhalation can be determined by one skilled in the art.
The compounds of the invention may also be administered topically, in which case the carrier will suitably contain a solution, ointment or gel base. The base may, for example, comprise one or more of the following substances: the concentration of the calcium-containing compound or pharmaceutically acceptable salt thereof in the topical formulation may be from about 0.1 to about 10% w/v (weight per unit volume).
The solution or suspension may also contain one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as vitamin C or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for adjusting the osmotic pressure such as sodium chloride or glucose. The parenteral formulations may be presented in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
Detailed Description
The following reaction scheme outlines the preparation steps for preparing the compounds of the present invention.
Reaction scheme
The present invention is described in detail by the following examples. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described.
Example 1: preparation of 2- (4-phenylpiperazin-1-ylcarbonyl) -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
Step A: preparation of 3- (thiophene-2-thio) propionic acid
Adding 0.04mol of 2-mercaptothiophene, 0.04mol of acrylic acid and 80mL of tetrahydrofuran into a 250mL round bottom flask, dropwise adding 11mL of triethylamine while stirring, heating and refluxing for reaction for 12h, after the reaction is finished, slightly cooling, and evaporating the tetrahydrofuran. After cooling, 40mL of ethyl acetate and 20mL of water were added, the pH of the solution was adjusted to 2 with 18% hydrochloric acid, the organic layers were collected, the aqueous layer was extracted with ethyl acetate, and the organic layers were combined and dried over anhydrous magnesium sulfate. And (3) carrying out suction filtration, evaporating the solvent from the filtrate, cooling, precipitating a brown solid, and recrystallizing by using petroleum ether to obtain a white solid with the yield of 5.82g and the yield of 77.4%. m.p. 43-45 ℃.
And B: preparation of 5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
A250 mL three-necked flask was charged with 0.02mol of 3- (thiophene-2-thio) propionic acid, 20mL of dichloromethane, and 2 drops of DMF, and a dichloromethane solution containing oxalyl chloride (2.2 mL of oxalyl chloride, 15mL of dichloromethane) was added dropwise with stirring under nitrogen protection and stirred at room temperature for 2 hours. The reaction mixture was cooled to-10 ℃ or lower with an ice salt bath, and a dichloromethane solution containing tin tetrachloride (1.15 mL of tin tetrachloride, 10mL of dichloromethane) was added dropwise with stirring. After the dripping is finished, stirring is carried out for 2h at the temperature of 0 ℃. To a three-necked flask, 30mL of water was added, the organic layer was extracted, the aqueous layer was extracted with dichloromethane, and the organic layers were combined. The organic layer was washed with a saturated sodium carbonate solution, water and a saturated sodium chloride solution in this order, and dried over anhydrous magnesium sulfate. And (3) carrying out suction filtration, evaporating the solvent from the filtrate, cooling to obtain a brown crude product, and recrystallizing by using petroleum ether to obtain a light yellow solid, wherein the yield is 2.75g and 80.9%. m.p. 59.0-60.5 ℃.1H-NMR(300MHz,DMSO-d6):δ2.77(t,2H,J＝6.6Hz),3.47(t,2H,J＝6.6Hz),7.35(d,1H,J＝5.4Hz),7.38(d,1H,J＝5.4Hz)。MS(m/z):171([M+H]+)。
And C: preparation of 2-trichloroacetyl-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
0.06mol of threeAluminum chloride and 20mL of methylene chloride were mixed, added to a 250mL round bottom flask, and cooled in an ice bath. Dropwise adding dichloromethane solution containing trichloroacetyl chloride (trichloroacetyl chloride 0.026mol, dichloromethane 25mL) under stirring for about 20min, stirring for 30min, and continuously dropwise adding 5, 6-dihydro-4H-thieno [2,3-b ] containing 0.02mol under ice bath]20mL of a solution of thiopyran-4-one in methylene chloride was added dropwise, the mixture was stirred at room temperature for 24 hours, the reaction mixture was poured into 100mL of water, the organic layer was extracted, the aqueous layer was extracted with methylene chloride, and the organic layers were combined and dried over anhydrous magnesium sulfate. Filtering, evaporating the solvent from the filtrate, and recrystallizing with ethanol. Pale yellow crystals were obtained, yield 2.95g, yield 47.0%. m.p. 152.5-154.0 ℃.1H-NMR(600MHz,CDCl3)δ:2.92(t,2H,J＝6.6Hz),3.45(t,2H,J＝6.6Hz),8.45(s,1H)；ESI-MS(m/z):312.9([M-H]-)。
Step D: preparation of 4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxylic acid
0.01mol of 2-trichloroacetyl-5, 6-dihydro-4H-thieno [2,3-b ] was added to a 250mL round-bottom flask]Reacting thiopyran-4-one, 0.013mol of sodium carbonate and 150mL of water at 60 ℃ for 15h, cooling to room temperature after the reaction is finished, performing suction filtration, adjusting the pH value of the filtrate to 2 by using hydrochloric acid, performing suction filtration, and washing the solid by using water to obtain a light yellow powdery solid, wherein the yield is 1.89g, the yield is 88.3%, and the m.p. is 201-203 ℃.1H-NMR(400MHz,DMSO-d6)δ:2.81(t,2H,J＝6.4),3.45(t,2H,J＝6.4),7.80(s,1H),13.43(s,1H)；ESI-MS(m/z):212.8([M-H]-)。
Step E: preparation of 2- (4-phenylpiperazin-1-ylcarbonyl) -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
In a 50mL round-bottom flask, 1.5mmol of 4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] was added]Thiopyran-2-carboxylic acid, 1.5mmol of 1-phenylpiperazine, 1.9mmol of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, 0.3mmol of 1-hydroxybenzotriazole, 1mL of triethylamine and 15mL of dried methylene chloride were stirred at room temperature for 48 hours, filtered, the filtrate was washed with 18% hydrochloric acid, saturated sodium carbonate, water and saturated sodium chloride in this order, and the organic layer was extracted and dried over anhydrous magnesium sulfate. Suction filtering, filtering the solutionEvaporating the solvent to obtain a crude product, and separating by silica gel column chromatography to obtain 0.28g of white solid yellow solid with the yield of 51.9%; mp is 138-140 ℃; IR (KBr, cm)-1):3425.0,3303.5,3084.8,3000.7,2922.0,2850.6,2815.3,1658.2,1600.1,1503.4,1426.7,1230.3,1178.6,997.7,905.0,758.4；1H-NMR(600MHz,CDCl3)δ：7.62(s,1H),7.30(t,J＝7.8Hz,2H),6.91～6.97(m,3H),3.92(t,J＝5.4Hz,4H),3.40(t,J＝6.0Hz,2H),3.24(t,J＝5.4Hz,4H),2.88(t,J＝6.0Hz,2H)；ESI-MSm/z:356.9([M-H]-)。
Example 2: preparation of 2- [4- (2-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis method of example 1, 0.28g of yellow solid was obtained with a yield of 47.5%; mp 173-175 ℃; IR (KBr, cm)-1):3424.6,3066.0,3008.3,2951.6,2910.2,2837.7,1652.0,1628.1,1585.5,1526.3,1476.9,1427.3,1391.3,1269.2,1231.3,1172.6,995.4,763.6,749.6；1H-NMR(600MHz,CDCl3)δ：7.61(s,1H),7.39(d,J＝8.4Hz,1H),7.23(d,J＝8.4Hz,1H),7.01～7.03(m,2H),3.94(t,J＝4.8Hz,4H),3.40(t,J＝6.6Hz,2H),3.10(t,J＝4.8Hz,4H),2.88(t,J＝6.6Hz,2H)；ESI-MS m/z:393.1([M+H]+),415.1([M+Na]+)。
Example 3: preparation of 2- [4- (2-ethylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
Following the synthesis procedure of example 1, a yellow solid was obtained in 74.1% yield; mp is 170-172 ℃; IR (KBr, cm)-1):3429.7,3092.6,3059.5,3026.4,2963.2,2943.9,2933.0,2895.8,2836.6,1652.7,1629.0,1527.0,1486.9,1425.3,1390.6,1254.3,1227.6,1173.4,997.4,726.5；1H-NMR(400MHz,CDCl3)δ：7.62(s,1H),7.14～7.24(m,2H),7.01～7.13(m,2H),3.83～3.99(m,4H),3.40(t,J＝6.4Hz,2H),2.92～2.96(m,4H),2.88(t,J＝6.4Hz,2H),2.73(q,J＝7.6Hz,2H),1.26(t,J＝7.6Hz,3H)；ESI-MS m/z:387.2([M+H]+),409.1([M+Na]+)。
Example 4: preparation of 2- [4- (4-fluorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis method of example 1, yellow crystals were obtained with a yield of 46.4%; mp 131-133 ℃; IR (KBr, cm)-1):3424.4,3105.9,3043.2,2986.9,2915.0,2892.2,2851.5,1671.0,1590.6,1510.3,1440.3,1391.0,1279.0,1224.1,1156.6,1000.8,822.0,734.0；1H-NMR(600MHz,CDCl3)δ：7.62(s,1H),7.00(d,J＝7.8Hz,2H),6.91(d,J＝7.8Hz,2H),3.90～3.94(m,4H),3.40(t,J＝6.0Hz,2H),3.13～3.18(m,4H),2.88(t,J＝6.0Hz,2H)；ESI-MS m/z:374.9([M-H]-)。
Example 5: preparation of 2- [4- (2-trifluoromethoxyphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis procedure of example 1, a white solid was obtained in 54.5% yield; mp is 122-124 ℃; IR (KBr, cm)-1):3425.0,2946.1,2917.6,2893.5,2839.5,1739.4,1652.2,1629.8,1525.6,1498.4,1427.3,1390.7,1265.3,1226.8,1171.9,996.8,911.3,760.2；1H-NMR(400MHz,CDCl3)δ：7.61(s,1H),7.19～7.25(m,2H),6.99～7.07(m,2H),3.90(t,J＝4.8Hz,4H),3.40(t,J＝6.4Hz,2H),3.10(t,J＝4.8Hz,4H),2.87(t,J＝6.4Hz,2H)；ESI-MS m/z:443.1([M+H]+),465.1([M+Na]+)。
Example 6: preparation of 2- [4- (2, 4-dimethylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis method of example 1, yellow crystals were obtained with a yield of 46.6%; mp is 216-218 ℃; IR (KBr, cm)-1):3421.8,3302.7,3096.7,3001.1,2948.7,2895.2,2855.8,2804.1,1661.5,1591.6,1520.0,1501.2,1428.5,1390.0,1258.0,1177.8,997.5,824.9；1H-NMR(400MHz,CDCl3)δ：7.61(s,1H),7.03(s,1H),6.99(d,J＝8.0Hz,1H),6.90(d,J＝8.0Hz,1H),3.89(t,J＝4.8Hz,4H),3.39(t,J＝6.4Hz,2H),2.92(t,J＝4.8Hz,4H),2.87(t,J＝6.4Hz,2H),2.30(s,3H),2.28(s,3H)；ESI-MS m/z:409.1([M+Na]+)。
Example 7: preparation of 2- [4- (3-bromophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
Following the synthesis procedure of example 1, a yellow solid was obtained in 43.1% yield; mp 156-158 ℃; IR (KBr, cm)-1):3441.6,3092.6,2913.1,2338.2,1733.3,1668.7,1587.7,1524.4,1484.2,1426.5,1234.4,1177.9,1046.7,997.1,982.3,932.6,842.4,763.4,682.3；1H-NMR(600MHz,CDCl3)δ：7.62(s,1H),6.97～7.02(m,2H),6.89～6.94(m,2H),3.90～3.94(m,4H),3.40(t,J＝6.0Hz,2H),3.14～3.18(m,4H),2.88(t,J＝6.0Hz,2H)；ESI-MS m/z:434.8([M-H]-)。
Example 8: preparation of 2- [4- (2-methyl-6-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis method of example 1, a white solid is obtained with a yield of 65.6%; mp 190-193 ℃; IR (KBr, cm)-1):3423.4,3313.6,3200.1,3089.7,2955.6,2914.6,2829.2,1665.4,1610.8,1525.9,1425.0,1389.5,1260.8,1223.8,1167.5,993.9,778.7,739.5,719.0；1H-NMR(400MHz,CDCl3)δ：7.61(s,1H),7.18(d,J＝7.6Hz,1H),7.10(d,J＝7.6Hz,1H),7.00(t,J＝7.6Hz,1H),4.08～4.21(m,2H),3.44～3.61(m,4H),3.40(t,J＝6.0Hz,2H),2.94～3.02(m,2H),2.87(t,J＝6.0Hz,2H),2.36(s,3H)；ESI-MS m/z:407.1([M+H]+),429.1([M+Na]+)。
Example 9: preparation of 2- [4- (2-methyl-3-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
Following the synthesis procedure of example 1, a yellow solid was obtained in 29.5% yield; mp 189-191 ℃; IR (KBr, cm)-1):3324.1,3091.2,3000.9,2944.9,2903.7,2816.3,1664.5,1609.5,1524.8,1453.7,1426.7,1662.0,1231.0,1173.7,995.0,798.2,719.9；1H-NMR(400MHz,CDCl3)δ：7.61(s,1H),7.14(dd,J1＝8.0Hz,J2＝1.2Hz,1H),7.10(t,J＝8.0Hz,1H),6.91(dd,J1＝8.0Hz,J2＝1.2Hz,1H),3.80～4.02(m,4H),3.40(t,J＝6.4Hz,2H),2.91～2.96(m,4H),2.88(t,J＝6.4Hz,2H),2.38(s,3H)；ESI-MS m/z:405.0([M-H]-)。
Example 10: preparation of 2- [4- (4-bromophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis method of example 1, a white solid is obtained with a yield of 70.8%; mp 160-162 ℃; IR (KBr, cm)-1):3418.1,3088.5,2998.2,2948.9,2917.0,2840.0,1654.1,1630.6,1588.7,1525.5,1490.7,1424.9,1346.0,1237.0,1173.7,1042.3,995.5,822.3,803.9,749.5,701.3,650.1,525.9；1H-NMR(400MHz,CDCl3)δ：7.61(s,1H),7.37(d,J＝9.2Hz,2H),6.80(d,J＝9.2Hz,2H),3.90(t,J＝5.2Hz,4H),3.40(t,J＝6.4Hz,2H),3.21(t,J＝5.2Hz,4H),2.88(t,J＝6.4Hz,2H)；ESI-MS m/z:437.2([M+H]+),459.0([M+Na]+),475.1([M+K]+)。
Example 11: preparation of 2- [4- (4-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
White crystals were obtained in 54.2% yield according to the synthesis method of example 1; mp 139-141 ℃; IR (KBr, cm)-1):3421.4,2921.6,2852.0,1630.6,1457.9,1384.3,1114.8,862.3；1H-NMR(400MHz,CDCl3)δ：7.61(s,1H),7.24(d,J＝8.8Hz,2H),6.85(d,J＝8.8Hz,2H),3.91(t,J＝5.2Hz,4H),3.40(t,J＝6.4Hz,2H),3.20(t,J＝5.2Hz,4H),2.88(t,J＝6.4Hz,2H)；ESI-MS m/z:390.9([M-H]-)。
Example 12: preparation of 2- [4- (3-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis procedure of example 1, a white solid was obtained in 35.6% yield; mp is 90-92 ℃; IR (KBr, cm)-1):3446.7,3092.0,2915.0,2845.4,1667.1,1590.7,1524.1,1428.2,1233.8,1177.6,1114.0,998.2,938.8,890.8,841.5,763.9,736.7；1H-NMR(600MHz,CDCl3)δ：7.61(s,1H),7.19(t,J＝7.8Hz,1H),6.86～6.89(m,2H),6.79(dd,J1＝7.8Hz,J2＝1.8Hz,1H),3.90(t,J＝5.1Hz,4H),3.40(t,J＝6.0Hz,2H),3.25(t,J＝5.1Hz,4H),2.87(t,J＝6.0Hz,2H)；ESI-MS m/z:390.9([M-H]-)。
Example 13: preparation of 2- [4- (3-trifluoromethyl-4-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
White crystals were obtained in 40.6% yield according to the synthesis method of example 1; mp 196-198 ℃; IR (KBr, cm)-1):3426.5,3106.6,2889.8,2900.8,2850.3,1668.0,1589.9,1521.9,1489.6,1428.6,1391.6,1310.8,1263.2,1238.6,1181.8,1000.7,950.1,850.9,817.5,736.9；1H-NMR(400MHz,CDCl3)δ：7.62(s,1H),7.38(d,J＝8.8Hz,1H),7.19(d,J＝2.8Hz,1H),6.98(dd,J1＝8.8Hz,J2＝2.8Hz,1H),3.93(t,J＝5.2Hz,4H),3.40(t,J＝6.4Hz,2H),3.27(t,J＝5.2Hz,4H),2.88(t,J＝6.4Hz,2H)；ESI-MS m/z:458.9([M-H]-)。
Example 14: preparation of 2- [4- (2-methylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis procedure of example 1, a white solid was obtained in 33.9% yield; mp 167-169 ℃; IR (KBr, cm)-1):3424.5,3108.5,3006.1,2945.1,2899.2,2853.7,2806.6,1656.8,1592.3,1521.5,1492.7,1434.8,1390.5,1277.4,1227.5,1179.7,1038.9,998.6,769.5；1H-NMR(400MHz,CDCl3)δ：7.62(s,1H),7.17～7.22(m,2H),6.99～7.04(m,2H),3.90(t,J＝4.8Hz,4H),3.40(t,J＝6.4Hz,2H),2.96(t,J＝4.8Hz,4H),2.88(t,J＝6.4Hz,2H),2.34(s,3H)；ESI-MS m/z:395.1([M+Na]+)。
Example 15: preparation of 2- [4- (4-methoxyphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
White crystals were obtained in 55.2% yield according to the synthesis method of example 1; mp 144-146 ℃; IR (KBr, cm)-1):3433.3,3094.3,3044.6,2999.7,2946.7,2912.7,2836.2,1736.8,1655.3,1626.5,1510.5,1454.1,1424.4,1281.2,1231.7,1144.9,1041.2,1033.4,996.4,825.6,796.4；1H-NMR(400MHz,CDCl3)δ：7.61(s,1H),6.92(d,J＝8.8Hz,2H),6.86(d,J＝8.8Hz,2H),3.91(t,J＝4.8Hz,4H),3.78(s,3H),3.40(t,J＝6.4Hz,2H),3.11(t,J＝4.8Hz,4H),2.88(t,J＝6.4Hz,2H)；ESI-MS m/z:387.1([M-H]-)。
Example 16: preparation of 2- [4- (4-methylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis procedure of example 1, a white solid was obtained in 53.6% yield; mp 169-172 ℃; IR (KBr, cm)-1):3421.4,3028.4,2952.8,2912.9,1655.1,1629.9,1512.8,1425.9,1388.7,1234.4,1174.9,997.6,811.1；1H-NMR(400MHz,CDCl3)δ：7.61(s,1H),7.11(d,J＝8.4Hz,2H),6.85(d,J＝8.4Hz,2H),3.91(t,J＝5.2Hz,4H),3.40(t,J＝6.4Hz,2H),3.18(t,J＝5.2Hz,4H),2.88(t,J＝6.4Hz,2H),2.29(s,3H)；ESI-MS m/z:395.1([M+Na]+)。
Example 17: preparation of 2- [4- (3-trifluoromethylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis method of example 1, yellow crystals are obtained with a yield of 50.0%; mp is 123-124 ℃; IR (KBr, cm)-1):3433.7,2906.1,2840.0,1665.8,1591.8,1524.0,1434.3,1392.8,1353.6,1312.1,1234.4,1166.3,1093.0,1000.4,945.0,877.7,789.3,697.2；1H-NMR(600MHz,CDCl3)δ：7.62(s,1H),7.38(t,J＝7.8Hz,1H),7.14(d,J＝7.8Hz,1H),7.12(s,1H),7.07(dd,J1＝7.8Hz,J2＝1.8Hz,1H),3.93(t,J＝5.1Hz,4H),3.40(t,J＝6.0Hz,2H),3.30(t,J＝5.1Hz,4H),2.88(t,J＝6.0Hz,2H)；ESI-MS m/z:424.9([M-H]-)。
Example 18: preparation of 2- [4- (2, 5-dimethylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis method of example 1, yellow crystals are obtained with a yield of 31.0%; mp 194-196 ℃; IR (KBr, cm)-1):3426.9,2921.2,2887.6,2855.1,2802.2,1661.0,1597.0,1523.2,1438.3,1393.4,1275.7,1229.6,1179.5,1045.4,993.3,816.0,730.8；1H-NMR(600MHz,CDCl3)δ：7.62(s,1H),7.09(d,J＝7.8Hz,1H),6.85(d,J＝7.8Hz,1H),6.82(s,1H),3.86～3.92(m,4H),3.40(t,J＝6.0Hz,2H),2.92～2.97(m,4H),2.88(t,J＝6.0Hz,2H),2.31(s,3H),2.29(s,3H)；ESI-MS m/z:387.2([M+H]+),409.2([M+Na]+),795.2([2M+Na]+)。
Example 19: preparation of 6, 6-dimethyl-2- (4-phenylpiperazin-1-ylcarbonyl) -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
Step A: preparation of 3-methyl-3- (thiophene-2-thio) butanoic acid
Adding 0.04mol of 2-mercaptothiophene, 0.04mol of 3-methyl-2-butenoic acid and 80mL of tetrahydrofuran into a 250mL round-bottom flask, dropwise adding 11mL of triethylamine under stirring, and heating and refluxing for reaction for 20h under the protection of nitrogen to finish the reaction. Tetrahydrofuran was distilled off, after cooling, 40mL of ethyl acetate and water were added, the pH of the solution was adjusted to 2 with 18% hydrochloric acid, the organic layers were collected, the aqueous layer was extracted with ethyl acetate, and the organic layers were combined and dried over anhydrous magnesium sulfate. And (4) carrying out suction filtration, evaporating the solvent from the filtrate, cooling, precipitating a brown solid, and recrystallizing by using petroleum ether to obtain a white powdery solid with the yield of 5.47g and the yield of 63.35%. m.p. 58-59 ℃.
And B: preparation of 6, 6-dimethyl-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
A250 mL three-necked flask was charged with 0.02mol of 3-methyl-3- (thiophene-2-thio) butanoic acid, 20mL of dichloromethane, and 2 drops of DMF, and a dichloromethane solution containing oxalyl chloride (2.2 mL of oxalyl chloride, 15mL of dichloromethane) was added dropwise with stirring under nitrogen protection, followed by stirring at room temperature for 2 hours. The reaction solution was cooled in an ice salt bath, and a dichloromethane solution containing tin tetrachloride (1.15 mL of tin tetrachloride, 10mL of dichloromethane) was added dropwise with stirring. Stirring for 2 h. To a three-necked flask, 30mL of water was added, the organic layer was extracted, the aqueous layer was extracted with dichloromethane, and the organic layers were combined. The organic layer was washed with a saturated sodium carbonate solution, water and a saturated sodium chloride solution in this order, and dried over anhydrous magnesium sulfate. And (3) carrying out suction filtration, evaporating the solvent from the filtrate, cooling to obtain a brown crude product, and recrystallizing with petroleum ether to obtain a light yellow powdery solid with the yield of 2.98g and the yield of 75.3%. m.p. 68-69 ℃.
And C: preparation of 6, 6-dimethyl-2-trichloroacetyl-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
0.06mol of aluminum trichloride and 20mL of methylene chloride were mixed, and the mixture was charged into a 250mL round-bottom flask and cooled in an ice bath. Dropwise adding dichloromethane solution containing trichloroacetyl chloride (trichloroacetyl chloride 0.026mol, dichloromethane 25mL) under stirring for about 20min, stirring for 30min, and continuously dropwise adding dichloromethane solution containing 6, 6-dimethyl-5, 6-dihydro-4H-thieno [2,3-b ] under ice bath]Solution of thiopyran-4-one in methylene chloride (6, 6-dimethyl-5, 6-dihydro-4H-thieno [2, 3-b)]0.02mol of thiopyran-4-one and 20mL of dichloromethane), stirring at room temperature for 24 hours after dropping, pouring the reaction mixture into 100mL of water, extracting an organic layer, extracting an aqueous layer with dichloromethane, combining the organic layers, and drying with anhydrous magnesium sulfate. Filtering, evaporating the solvent from the filtrate, and recrystallizing with ethanol. Yellow granular crystals were obtained with a yield of 3.25g, 43.3%. 157-159 ℃ in m.p. IR (KBr, cm)-1):3438,2965,2927,1662,1511,1389,1242,1206,1041,961,885,848,809,714,700,677；1H-NMR(300MHz,CDCl3):δ1.56(s,6H),2.81(s,2H),8.44(s,1H)；MS(m/z):345.1([M+H]+)。
Step D: preparation of 6, 6-dimethyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-2-carboxylic acid
Into a round-bottomed flask was added 0.01mol of 6, 6-dimethyl-2-trichloroacetyl-5, 6-dihydro-4H-thieno [2,3-b ] prepared as described above]Reacting thiopyran-4-one, 0.013mol of anhydrous sodium carbonate and water at 60 ℃ for 15h, cooling to room temperature after the reaction is finished, performing suction filtration, adjusting the pH value of the filtrate to 2 by using hydrochloric acid, performing suction filtration, and washing the solid by using water to obtain a light yellow powdery solid, wherein the yield is 2.16g, the yield is 78.8%, and the m.p. is 203-204 ℃. IR (KBr, cm)-1):3444,2964,2927,2360,2340,1663,1527,1432,1398,1387,1295,1275,1204,1068,921,879,755,695；1H-NMR(300MHz,CDCl3):δ1.55(s,6H),2.80(s,2H),8.19(s,1H)；MS(m/z):243.0([M+H]+)，265.0([M+Na]+)。
Step E: preparation of 6, 6-dimethyl-2- (4-phenylpiperazin-1-ylcarbonyl) -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
In a 50mL round-bottom flask, 1mmol of 6, 6-dimethyl-4-oxo-5, 6-dihydro-4H-thieno [2,3-b ] was added]Thiopyran-2-carboxylic acid, 1.5mmol of 1-phenylpiperazine, 1.38g (10mmol) of anhydrous potassium carbonate, 0.08g (0.5mmol) of potassium iodide and 25mL of dried acetone were heated under reflux for 4 hours, cooled, suction-filtered, and the solvent was evaporated to give a crude product, which was separated by silica gel column chromatography (methanol: chloroform ═ 1:25) to give 0.51g of a white solid in 44.0% yield. m.p. 152-154 ℃. IR (KBr, cm)-1):3437,2963,2921,2850,1675,1663,1635,1524,1433,1386,1207,998,881,841,755；1H-NMR(600MHz,CDCl3):δ1.54(s,6H),2.78(s,2H),3.24～3.25(t,4H),3.92～3.94(t,4H),6.91～6.95(m,3H),7.29～7.30(t,2H,J＝7.9Hz),7.62(s,1H)；MS(m/z):387.1([M+H]+),408.8([M+Na]+)。
Example 20: preparation of 6, 6-dimethyl-2- [4- (4-methylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis method of example 19, yellow crystals were obtained with a yield of 42.5%. m.p. 164-166 ℃. IR (KBr, cm)-1):3428,2919,2855,1663,1617,1518,1432,1385,1365,1274,1231,1204,1148,1040,1000,815,749；1H-NMR(300MHz,CDCl3):δ1.54(s,6H),2.29(s,3H),2.77(s,2H),3.17～3.20(t,4H),3.90～3.94(t,4H),6.85～6.88(d,2H,J＝8.2Hz),7.09～7.12(d,2H,J＝8.2Hz)7.62(s,1H)；MS(m/z):401.2([M+H]+)，423.2([M+Na]+)。
Example 21: preparation of 6, 6-dimethyl-2- [4- (4-fluorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis procedure of example 19, a yellow solid was obtained in 33.0% yield. m.p. 166-168 ℃. IR (KBr, cm)-1):3428,2957,2922,2857,1660,1619,1507,1433,1384,1273,1213,1145,1041,1001,919,832,816,707；1H-NMR(600MHz,CDCl3):δ1.54(s,6H),2.78(s,2H),3.14～3.16(t,4H),3.91～3.93(t,4H),6.89～6.92(m,2H),6.98～7.02(m,2H),7.62(s,1H)；MS(m/z):405.1([M+H]+)，427.2([M+Na]+)。
Example 22: preparation of 6, 6-dimethyl-2- [4- (4-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
The procedure was followed for the synthesis of example 19 to give a yellow solid in 7.93% yield. m.p. 172-174 ℃. IR (KBr, cm)-1):3437,2961,2921,2852,1730,1664,1598,1521,1497,1428,1386,1234,1212,1162,998,880,735；1H-NMR(600MHz,CDCl3):δ1.54(s,6H),2.78(s,2H),3.20～3.22(t,4H),3.91～3.93(t,4H),6.85～6.86(d,2H,J＝8.9Hz),7.23～7.25(d,2H,J＝8.9Hz),7.62(s,1H)；MS(m/z):421.0([M+H]+)，443.0([M+Na]+)。
Example 23: preparation of 6, 6-dimethyl-2- [4- (4-methoxyphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
Following the synthesis of example 19, a yellow solid was obtained in 71.7% yield. m.p. 148-149 ℃. IR (KBr, cm)-1):3444,2918,2849,1658,1605,1515,1459,1429,1386,1286,1248,1211,1189,1032,1004,877,820,738；1H-NMR(600MHz,CDCl3):δ1.54(s,6H),2.78(s,2H),3.11～3.12(t,4H),3.78(s,3H),3.91～3.92(t,4H),6.85～6.88(d,2H,J＝9.1Hz),6.94～6.97(d,2H,J＝9.1Hz),7.61(s,1H)；MS(m/z):417.1([M+H]+)，439.2([M+Na]+)。
Example 24: preparation of 6, 6-dimethyl-2- [4- (4-trifluoromethoxyphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis method of example 19, 0.38g of pale yellow solid was obtained with a yield of 27.0%. m.p. 135-137 ℃. IR (KBr, cm)-1):3425,2961,2922,2852,1675,1619,1520,1431,1387,1267,1239,1207,1156,1037,998,834,806,746；1H-NMR(300MHz,CDCl3):δ1.54(s,6H),2.78(s,2H),3.23～3.26(t,4H),3.94～3.98(t,4H),6.96～6.99(d,2H,J＝8.7Hz),7.14～7.17(d,2H,J＝8.7Hz),7.62(s,1H)；MS(m/z):471.2([M+H]+)，493.1([M+Na]+)，509.1([M+K]+)。
Example 25: preparation of 6, 6-dimethyl-2- [4- (2-fluorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis method of example 19, 0.35g of yellow solid was obtained with a yield of 28.9%. m.p. 189-191 ℃. IR (KBr, cm)-1)3447,2964,2917,2849,1734,1663,1609,1525,1502,1430,1396,1369,1268,1242,1209,1149,1035,1002,928,881,810,759；1H-NMR(300MHz,CDCl3):δ1.53(s,6H),2.77(s,2H),3.12～3.15(t,4H),3.91～3.95(t,4H),6.91～7.06(m,4H),7.61(s,1H)；MS(m/z):405.1([M+H]+)，427.2([M+Na]+)。
Example 26: preparation of 6, 6-dimethyl-2- [4- (3-chloro-4-fluorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
The synthesis procedure of example 19 was followed to give a pale yellow solid in 63.9% yield.
m.p.:165-167℃。IR(KBr,cm-1):3428,2920,2851,1666,1607,1511,1430,1386,1235,1209,1111,1035,1000,953,894,787,728；1H-NMR(300MHz,CDCl3):δ1.54(s,6H),2.78(s,2H),3.16～3.19(t,4H),3.92～3.95(t,4H),6.80～6.86(dt,1H,J1＝8.9Hz,J2＝3.0Hz),6.96～6.99(dd,1H,J1＝6.1Hz,J2＝3.0Hz),7.04～7.10(t,1H,J＝8.9Hz),7.61(s,1H)；MS(m/z):439.1([M+H]+)，461.1([M+Na]+)。
Example 27: preparation of 6, 6-dimethyl-2- {4- [3, 5-bis (trifluoromethyl) phenyl ] piperazin-1-ylcarbonyl } -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis method of example 19, 0.66g of white crystals was obtained with a yield of 42.4%. 196-197 ℃ in m.p. IR (KBr, cm)-1):3424,3075,2965,2894,2863,1668,1634,1524,1440,1388,1277,1176,1140,994,962,872,700；1H-NMR(600MHz,CDCl3):δ1.55(s,6H),2.79(s,2H),3.38～3.40(t,4H),3.96～3.97(t,4H),7.26(s,2H),7.35(s,1H),7.63(s,1H)；MS(m/z):523.2([M+H]+)，545.1([M+Na]+)。
Example 28: preparation of 6, 6-dimethyl-2- [4- (3-trifluoromethylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
According to the synthesis method of example 19, 0.54g of pale yellow solid was obtained with a yield of 39.7%. m.p. 143-144 ℃. IR (KBr, cm)-1):3450,2965,2926,1666,1584,1521,1458,1433,1390,1317,1207,1160,1113,1073,991,776；1H-NMR(300MHz,CDCl3):δ1.55(s,6H),2.78(s,2H),3.30～3.31(t,4H),3.93～3.95(t,4H),7.07～7.09(dd,1H,J1＝8.1Hz,J2＝2.1Hz),7.13～7.16(m,2H),7.38～7.40(t,1H,J＝8.1Hz),7.63(s,1H)；MS(m/z):455.2([M+H]+)，476.9([M+Na]+)。
Example 29: preparation of 6, 6-dimethyl-2- [4- (3, 4-difluorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
The synthesis procedure of example 19 was followed to give a pale yellow solid in 19.0% yield. m.p. 220-221 ℃. IR (KBr, cm)-1):3357,3077,2923,1652,1618,1558,1515,1419,1270,1230,1206,1108,877,852；1H-NMR(600MHz,CDCl3):δ1.55(s,6H),2.80(s,2H),3.24～3.26(t,4H),3.90～3.92(t,4H),7.12～7.17(dd,1H,J1＝18.4Hz,J2＝8.9Hz),7.21～7.23(m,1H),7.38～7.40(ddd,1H,J1＝12.0Hz,J2＝7.1Hz,J3＝2.6Hz),7.63(s,1H)；MS(m/z):423.1([M+H]+)，445.2([M+Na]+)。
Example 30: preparation of 6, 6-dimethyl-2- [4- (3-bromophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one
Following the synthesis procedure of example 19, a light yellow solid was obtained in 20.1% yield. m.p. 172-174 ℃. IR (KBr, cm)-1):3442,2962,2923,2850,1663,1589,1520,1483,1393,1239,1205,1162,1040,995,767；1H-NMR(600MHz,CDCl3):δ1.54(s,6H),2.78(s,2H),3.24～3.26(t,4H),3.90～3.92(t,4H),6.83～6.85(dd,1H,J1＝8.2Hz,J2＝1.9Hz),7.02～7.05(m,1H),7.13～7.15(t,1H,J＝8.2Hz),7.62(s,1H)；MS(m/z):465.9([M+H]+)，486.9([M+Na]+)。
Pharmacological examples
Example 31: inhibition effect on human lung adenocarcinoma cells A549 and human large cell lung cancer cells NCI-H460
Positive drug: gefitinib, available from Dalian Meiren Biotechnology Ltd.
Cell lines: human lung adenocarcinoma cells a 549; human large cell lung carcinoma cell NCI-H460 (Shanghai cell Bank of Chinese academy).
Cell culture conditions: RMPI1640 medium: fetal bovine serum 1:9, penicillin: 100 units/ml; streptomycin: 100 units/ml. At 37 ℃ with 5% CO2And (5) culturing and subculturing in a constant-temperature incubator.
Main reagents for the test: RMPI1640 medium (GIBCO, usa); fetal bovine serum (Hyclone, USA); pancreatin (Sigma, usa); thiazole blue (MTT, Sigma, usa);
main instruments for the test: autoclave SN510C (YAMATO, japan); CO2 incubator (SANYO, Japan), inverted microscope (CKX31, OLYMPUS, Japan), enzyme labeling photometer (MULTISKAN MC, England).
The test method comprises the following steps: the test drug (stock solution concentration: 4mM) was first prepared into a solution of 80. mu.M using RM 1640. After the cells are cultured to a logarithmic growth phase, digesting adherent cells for about 5min by using 0.25% pancreatin digestive juice, adding 10% fetal calf serum RMPI1640 culture medium to stop digestion, blowing and beating the cells into a cell suspension, transferring the cell suspension into a 15ml centrifuge tube, performing 1000-turn centrifugation for 5min (the suspended growing cells do not need to be digested, directly transferring the cell suspension into the 15ml centrifuge tube, performing 1000-turn centrifugation for 5min), discarding the supernatant, adding 10% fetal calf serum RMPI1640 culture medium, blowing and beating the cell suspension uniformly to prepare a single cell suspension, and adjusting the concentration of the cell suspension to be 3.0 multiplied by 10 by uniformly4Spreading the cell suspension in a 96-well plate with each well being 200 μ l, each group having 3 wells; 3 wells were left separately and 200. mu.l of 10% fetal bovine serum RMPI1640 medium was added to each well as a blank control. After further culturing for 24h, each group of the experimental groupAdding 2 mul of test medicine with the concentration of 80 mul; RMPI 16402 μ l was added to the control group; and (3) continuing culturing for 24h, taking out the culture plate 4h before finishing culturing, adding 20 mu l of MTT (methanol to toluene) of 5mg/ml into each hole (keeping out of the sun), continuing culturing, after finishing culturing, absorbing and removing the culture medium, adding 150 mu l of DMSO into each hole, shaking up uniformly, and measuring the absorbance value on a microplate reader at the wavelength of 562 nm. Repeat 3 times.
The cell growth inhibition rate calculation formula is as follows: the growth inhibition rate was ═ 1- (experimental absorbance average-blank absorbance average)/(control absorbance average-blank absorbance average) ] × 100%.
The experiment performed on the compound of the invention shows that the compound has an inhibitory effect on the cell proliferation of human lung adenocarcinoma cells A549 with high EGFR expression and human large cell lung cancer cells NCI-H460, and the inhibition rate is listed as follows:
example 32: inhibition of human breast cancer cells MCF-7
The experimental method comprises the following steps: human breast cancer cell MCF-7 is used as a test cell line and cultured in RPM I-1640 culture solution containing 10% (w) fetal calf serum for 24 hours at 37 ℃ in a CO2 culture box with the volume fraction of 5%. Cells in logarithmic growth phase (1.5X 10) were taken4one/mL) was inoculated into a 96-well plate at a concentration of 100. mu. mol. multidot.L per well-1And measuring the light absorption value of the target compound and the positive control drug tamoxifen at 490nm by using an enzyme-labeling instrument. According to the formula: the cell growth inhibition rate was 1- (number of cells in addition well/number of cells in control well) × 100%, and the cell growth inhibition rate at a concentration of 100 μ M was calculated. The inhibition rates for some samples were as follows:
the experimental result shows that the screened partial compounds have the inhibiting effect on the growth of human breast cancer cells MCF-7 at the concentration of 100 mu M.
In examples 33-53, "active compound" refers to a compound of formula I, or a salt or solvate thereof. The following non-limiting examples illustrate formulations for different topical administration modes. In formulations for transdermal administration, the active compound is generally used in an amount of 0.001 to 0.2% w/w), preferably 0.01 to 0.1% w/w).
Example 33: tablet formulation
25-1000mg of active compound, 45mg of starch, 35mg of microcrystalline cellulose, 4mL of polyvinylpyrrolidone (as a 10% aqueous solution), 4.5mg of sodium carboxymethylcellulose, 0.5mg of magnesium stearate, and 1mg of talc.
Example 34: suspending agent formula
0.1-1000mg of active compound, 50mg of sodium carboxymethylcellulose, 1.25mg of syrup, 0.1mg of sodium benzoate, a proper amount of flavoring agent and a proper amount of coloring agent, and adding pure water to 5 mL.
Example 35: aerosol formulations
0.25mg of active compound, 25-75mL of ethanol and 70mg of propellant 22 (chlorodifluoromethane).
Example 36: suppository formula
250mg of active compound, 2000mL of saturated fatty acid glycerides.
Example 37: injectable formulation
50mg of active compound, 1000mL of isotonic saline solution.
Example 38: ointment formulation
0.025g of micronized active compound, 10g of liquid paraffin, and 100g of soft white wax.
Example 39: ointment formulation
0.025g of active compound, 5g of propylene glycol, 5g of sorbitan sesquioleate, 10g of liquid paraffin and 100g of soft white wax.
Example 40: oil-in-water cream formulation
0.025g of active compound, 5g of cetyl alcohol, 5g of glycerol monostearate, 10g of liquid paraffin, 10002 g g of Ce tomacriol, 0.1g of citric acid, 0.2g of sodium citrate, 35g of propylene glycol and water to 100 g.
Example 41: oil-in-water cream formulation
0.025g of micronized active compound, 15g of soft white wax, 5g of liquid paraffin, 5g of cetyl alcohol, 2g of Sorbimcarol stearate, 0.5g of sorbitan monostearate, 0.2g of sorbic acid, 0.1g of citric acid, 0.2g of sodium citrate, and water to 100 g.
Example 42: water-in-oil cream formulation
0.025g of active compound, 35g of soft white wax, 5g of liquid paraffin, 5g of sorbitan sesquioleate, 0.2g of sorbic acid, 0.1g of citric acid and 0.2g of sodium citrate, and water is added until the weight is 100 g.
Example 43: lotion formulation
0.25g of active compound, 0.5mL of isopropanol, 3mg of carboxyvinyl polymer, a suitable amount of NaOH and water to 1 g.
Example 44: suspension formulation for injection
0.05-10mg of active compound, 7mg of sodium carboxymethylcellulose, 7mg of NaCl, 0.5mg of polyoxyethylene (20) sorbitan monooleate, 8mg of benzyl alcohol, and sterile water to 1 ml.
Example 45: aerosol formulation for oral and nasal inhalation
0.1% w/w active compound, 0.7% w/w sorbitan trioleate, 24.8% w/w trichlorofluoromethane, 24.8% w/w dichlorotetrafluoroethane and 49.6% w/w dichlorodifluoromethane.
Example 46: atomized solution formulation
7mg of active compound, 5mg of propylene glycol, water to 10 g.
Example 47: powder formulations for inhalation
Gelatine capsules were filled with a mixture of the following ingredients, micronised active compound 0.1mg, lactose 20mg and the powder was inhaled with the aid of an inhalation device.
Example 48: powder formulations for inhalation
The spheronized powder was loaded into a multi-dose powder inhaler containing 0.1mg of micronized active compound per dose.
Example 49: powder formulations for inhalation
The spheronized powder was loaded into a multi-dose powder inhaler containing 0.1mg of micronized active compound and 1mg of micronized lactose per dose.
Example 50: capsule formulation
1.0 part of active compound, 321mg of small sugar spheres, 306.6 mg of Aquacoat ECD, 0.5mg of acetyl tributyl citrate, 800.1 mg of Tween-800, 100-5517.5 mg of Eudragit L, 1.8mg of triethyl citrate, 8.8mg of talcum powder and 0.lmg of defoamer MMS.
Example 51: capsule seedling formula
2.0mg of active compound, 305mg of small sugar spheres, Aquocoat ECD 305.0 mg, acetyl tributyl citrate 0.4mg, Tween-800.14 mg, Eudragit NE30D 12.6.6 mg, Eudragit S10012.6 mg, talc 0.l6 mg.
Example 52: enema formula
0.2mg of active compound, 25mg of sodium carboxymethylcellulose, 0.5mg of disodium ethylenediaminetetraacetate, 0.8mg of methylparaben, 0.2mg of propylparaben, 7mg of sodium chloride, 1.8mg of citric acid, 800.01 mg of tween-800, and 1mL of pure water.
Example 53: formulation containing liposome
A. Preparation of the instillation formulation
Mixing synthesized dipalmitoyl in a glass tubeLecithin (45mg), dimyristoyl lecithin (7mg), dipalmitoyl phosphatidylglycerol (1mg) and (active compound (5mg), all components were dissolved in chloroform with N2Adding an aqueous solution (0.9% NaCl) to the lipids, forming liposomes at a temperature above the phase inversion temperature of the lipids, the resulting suspension containing liposomes ranging in size from very small vesicles to 2 μm.
B. Preparation of formulations for inhalation
Liposomes were prepared as in example A, with an aqueous solution containing 10% lactose at a 7:3 lactose to lipid ratio. The liposome suspension was frozen with dry ice and freeze-dried, and the dried product was micronized, and the Mass Mean Aerodynamic Diameter (MMAD) of the resulting particles was about 2 μm.
The foregoing is directed to preferred embodiments of the present invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, and the scope thereof is determined by the claims that follow. However, any simple modification, equivalent change and modification of the above embodiments according to the technical essence of the present invention are within the protection scope of the technical solution of the present invention.

Claims (9)

1. A compound of formula (I), prodrugs and pharmaceutically active metabolites thereof and pharmaceutically acceptable salts thereof:
wherein,
r is independently selected from hydrogen, methyl;
r' is independently selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, cyano, halogen, amino, nitro, trifluoromethyl, or trifluoromethoxy.
2. The compound of claim 1, prodrugs and pharmaceutically active metabolites thereof and pharmaceutically acceptable salts thereof:
wherein,
r is independently selected from hydrogen, methyl;
r' is independently selected from hydrogen, methyl, ethyl, methoxy, ethoxy, hydroxy, cyano, fluoro, chloro, bromo, iodo, amino, nitro, trifluoromethyl, or trifluoromethoxy.
3. The compound of claim 1 or 2, prodrugs and pharmaceutically active metabolites thereof and pharmaceutically acceptable salts thereof:
wherein,
r is independently selected from hydrogen, methyl; r' is independently selected from hydrogen, 2-chloro, 2-ethyl, 4-fluoro, 2-trifluoromethoxy, 2, 4-dimethyl, 3-bromo, 2-methyl-6-chloro, 2-methyl-3-chloro, 4-bromo, 4-chloro, 3-trifluoromethyl-4-chloro, 2-methyl, 4-methoxy, 4-methyl, 3-trifluoromethyl, 2, 5-dimethyl, 2-fluoro, 3-chloro-4-fluoro, 3, 5-bis (trifluoromethyl), 3, 4-difluoro, or 3-bromo.
4. The compound of claim 1, prodrugs and pharmaceutically active metabolites thereof, and pharmaceutically acceptable salts thereof, selected from the group consisting of:
2- (4-phenylpiperazin-1-ylcarbonyl) -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (2-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (2-ethylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (4-fluorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (2-trifluoromethoxyphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (2, 4-dimethylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (3-bromophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (2-methyl-6-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (2-methyl-3-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (4-bromophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (4-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (3-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (3-trifluoromethyl-4-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (2-methylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (4-methoxyphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (4-methylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (3-trifluoromethylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
2- [4- (2, 5-dimethylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
6, 6-dimethyl-2- (4-phenylpiperazin-1-ylcarbonyl) -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
6, 6-dimethyl-2- [4- (4-methylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
6, 6-dimethyl-2- [4- (4-fluorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
6, 6-dimethyl-2- [4- (4-chlorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
6, 6-dimethyl-2- [4- (4-methoxyphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
6, 6-dimethyl-2- [4- (4-trifluoromethoxyphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
6, 6-dimethyl-2- [4- (2-fluorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
6, 6-dimethyl-2- [4- (3-chloro-4-fluorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
6, 6-dimethyl-2- {4- [3, 5-bis (trifluoromethyl) phenyl ] piperazin-1-ylcarbonyl } -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
6, 6-dimethyl-2- [4- (3-trifluoromethylphenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
6, 6-dimethyl-2- [4- (3, 4-difluorophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one;
6, 6-dimethyl-2- [4- (3-bromophenyl) piperazin-1-ylcarbonyl ] -5, 6-dihydro-4H-thieno [2,3-b ] thiopyran-4-one.
5. A process for the preparation of compounds, prodrugs and pharmaceutically active metabolites thereof, and pharmaceutically acceptable salts thereof, according to claim 1, characterized in that: the reaction process is as follows:
6. a pharmaceutical composition comprising as active ingredient a compound according to any one of claims 1 to 4, prodrugs and pharmaceutically active metabolites thereof and pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier or excipient or diluent.
7. Use of compounds according to any of claims 1 to 4, prodrugs and pharmaceutically active metabolites thereof and pharmaceutically acceptable salts thereof or pharmaceutical compositions according to claim 5 for the manufacture of a medicament for the treatment of diseases associated with dysregulation of epidermal growth factor receptor signalling.
8. Use according to claim 7, characterized in that: the epidermal growth factor receptor is HER-1, HER-2, HER-3 or HER-4.
9. Use according to claim 7, characterized in that: the related diseases of the dysregulation of the epidermal growth factor receptor signal transduction are non-small cell lung cancer, gastric cancer, breast cancer, ovarian cancer, renal cell carcinoma, colorectal cancer, bladder cancer or head and neck squamous cell carcinoma.
CN201810537980.7A 2018-05-30 2018-05-30 Thienopyran formyl piperazine compound and medical application thereof Active CN108822126B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810537980.7A CN108822126B (en) 2018-05-30 2018-05-30 Thienopyran formyl piperazine compound and medical application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810537980.7A CN108822126B (en) 2018-05-30 2018-05-30 Thienopyran formyl piperazine compound and medical application thereof

Publications (2)

Publication Number Publication Date
CN108822126A true CN108822126A (en) 2018-11-16
CN108822126B CN108822126B (en) 2020-05-15

Family

ID=64146306

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810537980.7A Active CN108822126B (en) 2018-05-30 2018-05-30 Thienopyran formyl piperazine compound and medical application thereof

Country Status (1)

Country Link
CN (1) CN108822126B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113024506A (en) * 2021-03-18 2021-06-25 合肥工业大学 Process for preparing 3-formyltetrahydrothiopyran compounds
CN115160290A (en) * 2022-08-03 2022-10-11 广西大学 Synthetic method of 2-thiopheneacetic acid
WO2023139248A1 (en) * 2022-01-21 2023-07-27 Ecole Polytechnique Federale De Lausanne (Epfl) Inhibitors of acyl protein thioesterases against microbial infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082757A (en) * 1976-12-10 1978-04-04 Warner-Lambert Company Amides of 4-hydroxy-6H-thieno[2,3-b]thiopyran-5-carboxylic acid-7,7-dioxide
CN101426795A (en) * 2006-04-21 2009-05-06 Zach系统股份公司 Process for preparing dorzolamide
CN103415524A (en) * 2011-03-10 2013-11-27 Zach系统股份公司 Asymmetric reduction process
CN103626787A (en) * 2013-12-10 2014-03-12 沈阳药科大学 Thienothio compound and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082757A (en) * 1976-12-10 1978-04-04 Warner-Lambert Company Amides of 4-hydroxy-6H-thieno[2,3-b]thiopyran-5-carboxylic acid-7,7-dioxide
CN101426795A (en) * 2006-04-21 2009-05-06 Zach系统股份公司 Process for preparing dorzolamide
CN103415524A (en) * 2011-03-10 2013-11-27 Zach系统股份公司 Asymmetric reduction process
CN103626787A (en) * 2013-12-10 2014-03-12 沈阳药科大学 Thienothio compound and application thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113024506A (en) * 2021-03-18 2021-06-25 合肥工业大学 Process for preparing 3-formyltetrahydrothiopyran compounds
WO2023139248A1 (en) * 2022-01-21 2023-07-27 Ecole Polytechnique Federale De Lausanne (Epfl) Inhibitors of acyl protein thioesterases against microbial infections
CN115160290A (en) * 2022-08-03 2022-10-11 广西大学 Synthetic method of 2-thiopheneacetic acid

Also Published As

Publication number Publication date
CN108822126B (en) 2020-05-15

Similar Documents

Publication Publication Date Title
BRPI0805826B1 (en) spiro-substituted compounds, pharmaceutical composition and use
CN108822126B (en) Thienopyran formyl piperazine compound and medical application thereof
WO2020233641A1 (en) Compound used as ret kinase inhibitor and application thereof
CN103874494A (en) combination therapy using pyridopyrimidinone inhibitors of PI3K/MTOR with bendamustine and/or rituximab to treat hematological malignancies
CN102971312A (en) Pyrrolyl substituted dihydroindol-2-one derivatives, preparation methods and uses thereof
IL298132A (en) Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1h-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7h)-one
CN101735276A (en) Water-soluble phosphate monoester derivatives and application thereof
CN103360317A (en) Dicyclo-substituted pyrazolone azo derivatives, as well as preparation method and use thereof
CN108586485B (en) 1- (4-hydroxyiminothieno [2,3-b ] thiopyranoformyl) piperazine compound and application thereof
CN111454229B (en) Dihydronaphthoisoxazole derivative and application thereof in antitumor drugs
CN110467616B (en) Preparation and application of triazolopyrazine compound containing heteroaryl substituted pyridazinone structure
CN108484635B (en) 4H-thieno [2,3-b ] thiopyran-4-one compound and application thereof
US9902709B2 (en) Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition
JP2022517396A (en) EGFR inhibitor salt, crystalline form and method for producing it
CN108822127B (en) 4-hydroxyiminothieno [2,3-b ] thiopyran-2-carboxamides and their use
CN103864765B (en) Benzazepine analog derivative containing five-membered ring, Preparation Method And The Use
CN108586484B (en) Thienopyran carboxamides and their use
WO2019001307A1 (en) Amide compound, composition containing same, and use thereof
CN108822125B (en) 1- (thieno [2,3-b ] thiopyranoformyl) -4-aliphatic alkyl piperazine compound and medical application thereof
CA3084846A1 (en) Heteroaryl amide compounds, preparation method therefor, pharmaceutical compositions thereof, and applications thereof
CN111362924B (en) Deuterated pyrimidine derivatives and uses thereof
CN104292211A (en) Desloratadine nitric oxide donor, and preparation method and application thereof
IL298864A (en) Alkenyl pyrimidine compound, preparation method therefor, and application thereof
CN103159741A (en) Preparation and application of novel tyrosine kinase inhibitor
WO2020038279A1 (en) Substituted pyrazole compound, and preparation method, pharmaceutical composition, and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant